Skip to main content
3 April 2025
Last updated:
Sunday 30 March 2025
User account anon menu
Login
Register and subscribe
Search
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form
Menu
Breadcrumb
Home
Research Directory
Research Directory
Analysis of Special Protocol Assessments for oncology
Read more
A good beginning in the perilous biotech business
Read more
Transgene in vanguard of oncolytic virus therapy
Read more
A new business model for Pharma
Read more
US Special Protocol Assessments for Oncology
Read more
European biotechs start to look undervalued
Read more
An interview with Thomas Lönngren -- Managing change at the EMA
Read more
JAK2 inhibitors: a breakthrough in oncology?
Read more
European Commission lifts funding for innovation
Read more
Boehringer Ingelheim opts for nimble approach
Read more
Pagination
First page
« First
Previous page
‹‹
…
Page
70
Page
71
Page
72
Page
73
Current page
74
Page
75
Page
76
Page
77
Page
78
…
Next page
››
Last page
Last »
Home
News
News
Appointments
Events
About MedNous
Who We Are
Editorial Board
Editorial Policy
Research Directory
Research Directory
Organisations
Interviewees
Terms
Topics
Contact Us
Contact Form